Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Work In Process: 2015-2024

Historic Work In Process for Amphastar Pharmaceuticals (AMPH) over the last 10 years, with Dec 2024 value amounting to $32.8 million.

  • Amphastar Pharmaceuticals' Work In Process rose 17.89% to $42.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.5 million, marking a year-over-year increase of 17.89%. This contributed to the annual value of $32.8 million for FY2024, which is 6.44% up from last year.
  • As of FY2024, Amphastar Pharmaceuticals' Work In Process stood at $32.8 million, which was up 6.44% from $30.8 million recorded in FY2023.
  • Amphastar Pharmaceuticals' Work In Process' 5-year high stood at $37.3 million during FY2020, with a 5-year trough of $30.8 million in FY2023.
  • Moreover, its 3-year median value for Work In Process was $32.8 million (2024), whereas its average is $33.6 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Work In Process rose by 11.39% in 2022 and then decreased by 16.90% in 2023.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Work In Process stood at $37.3 million in 2020, then decreased by 10.63% to $33.3 million in 2021, then grew by 11.39% to $37.1 million in 2022, then dropped by 16.90% to $30.8 million in 2023, then grew by 6.44% to $32.8 million in 2024.